New four-drug cocktail targets tough liver cancers with promising early trial
NCT ID NCT07350070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of four treatments for people with liver cancer that cannot be removed by surgery and who also have high blood pressure in the liver (portal hypertension). The goal is to see if adding a blood-pressure drug (carvedilol) to standard cancer therapies (TACE, immunotherapy, and a targeted drug) can improve tumor shrinkage and safety. About 78 adults aged 18-75 with newly diagnosed liver cancer will take part. The approach aims to control the disease while protecting the liver.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Hepatobiliary and Pancreatic Oncology
Fuzhou, Fujian, China
-
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
-
Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
-
Hubei Province Tahe Hospital
Taihe, Hubei, China
-
Organ Transplant Department,Qilu Hospital, Cheeloo College of Medicine, Shandong University,
Jinan, Shandong, 250012, China
-
Qingdao University Affiliated Hospital
Qingdao, Shandong, China
-
Shandong First Medical University Affiliated Provincial Hospital
Jinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- A new procedure may offer relief for Cirrhosis-Related fluid buildup
- Can extra doses of an old drug reverse liver scarring?
- Can liver damage predict how drugs behave?
- Better crystal ball for liver crisis: new scores put to the test
- Blood thinner may stop early cirrhosis from turning deadly — a major trial puts it to the test